Literature DB >> 19264364

Emotion dysregulation and schizotypy.

Julie D Henry1, Melissa J Green, Corinne Restuccia, Amber de Lucia, Peter G Rendell, Skye McDonald, Jessica R Grisham.   

Abstract

In schizophrenia, blunted affect has been argued to reflect difficulties with the amplification of emotion expressive behavior. The aim of the present study was to assess whether ostensibly healthy individuals vulnerable to schizophrenia present with similar difficulties. In the first component of the study, 843 non-clinical participants completed the Schizotypal Personality Questionnaire, of which 27 scoring in the upper 15% (high schizotypy group) and 27 scoring in the lower 15% (low schizotypy group) were asked to watch amusing film clips, whilst engaging in different emotion regulatory strategies, and specifically, amplify the expression of an experienced emotion ('amplification') or suppress the expression of an experienced emotion ('suppression'). The results indicate that highly schizotypal participants present with specific difficulties with the amplification (but not suppression) of emotion expressive behavior. These difficulties are significantly correlated with total negative schizotypy, particularly blunted affect. In the second component of the study, an individual differences approach was used to assess the interrelationship between self-reported use of suppression and schizotypy in an independent sample of 204 community volunteers. The results suggest that, although blunted affect is associated with increased use of suppression, it cannot be regarded as the primary mechanism underpinning this disturbance. Implications for understanding blunted affect in schizophrenia and related disorders are discussed.

Entities:  

Mesh:

Year:  2009        PMID: 19264364     DOI: 10.1016/j.psychres.2008.01.007

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  7 in total

1.  The Relevance of Emotion Regulation in Explaining Why Social Exclusion Triggers Paranoia in Individuals at Clinical High Risk of Psychosis.

Authors:  Tania M Lincoln; Johanna Sundag; Björn Schlier; Anne Karow
Journal:  Schizophr Bull       Date:  2018-06-06       Impact factor: 9.306

2.  Social cognition in schizophrenia, Part 2: 12-month stability and prediction of functional outcome in first-episode patients.

Authors:  William P Horan; Michael F Green; Michael DeGroot; Alan Fiske; Gerhard Hellemann; Kimmy Kee; Robert S Kern; Junghee Lee; Mark J Sergi; Kenneth L Subotnik; Catherine A Sugar; Joseph Ventura; Keith H Nuechterlein
Journal:  Schizophr Bull       Date:  2011-03-07       Impact factor: 9.306

3.  Negative schizotypal traits predict the reduction of reward motivation in effort-reward imbalance.

Authors:  Yong-Jie Yan; Hui-Xin Hu; Ling-Ling Wang; Yi-Jing Zhang; Simon S Y Lui; Jia Huang; Raymond C K Chan
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2022-05-31       Impact factor: 5.270

Review 4.  Schizotypal personality disorder: a current review.

Authors:  Daniel R Rosell; Shira E Futterman; Antonia McMaster; Larry J Siever
Journal:  Curr Psychiatry Rep       Date:  2014-07       Impact factor: 5.285

5.  Experience of pleasure and emotional expression in individuals with schizotypal personality features.

Authors:  Yan-fang Shi; Yi Wang; Xiao-yan Cao; Ya Wang; Yu-na Wang; Ji-gang Zong; Ting Xu; Vincent W S Tse; Xiao-lu Hsi; William S Stone; Simon S Y Lui; Eric F C Cheung; Raymond C K Chan
Journal:  PLoS One       Date:  2012-05-16       Impact factor: 3.240

6.  Implicit emotion regulation deficits in individuals with high schizotypal traits: an ERP study.

Authors:  Delhii Hoid; Dong-Ni Pan; Yi Wang; Xuebing Li
Journal:  Sci Rep       Date:  2020-03-03       Impact factor: 4.379

7.  Using questionnaires and task-related EEG signals to reveal hindered reappraisal and biased suppression in individuals with high schizotypal traits.

Authors:  Dong-Ni Pan; Delhii Hoid; Zhen-Hao Wang; Yi Wang; Xuebing Li
Journal:  Sci Rep       Date:  2020-03-26       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.